Research Summary

Research Summary
I am a medical oncologist specializing in hematologic malignancy, with a particular emphasis on Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, and skin lymphomas. I have conducted numerous clinical trials in each of these areas. My laboratory research focuses on developing patient-derived murine models for T cell lymphomas, as well as conducting pre-clinical studies of novel agents.

Physician Biography
Dr. Ai specializes in the research and treatment of non-Hodgkin’s lymphoma, Hodgkin’s lymphoma, cutaneous lymphoma and bone marrow transplantation. She cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center and Department of Dermatology. She serves as a co-director of the UCSF Cutaneous Lymphoma Program. Dr. Ai graduated top of her class from Beijing University in cell biology and genetics. She earned a Ph.D. in microbiology and immunology, as well as her M.D. degree from Stanford University School of Medicine. After a residency in medicine at UCSF and an oncology fellowship at Stanford University, Dr. Ai joined the faculty at UCSF in 2007. She serves on both the Hodgkin’s lymphoma and T cell lymphoma committees, as well as the International Program of the National Comprehensive Cancer Care Network (NCCN). Dr. Ai’s research focuses on novel approaches to lymphoma treatment, especially targeted agents for T cell lymphomas. She has published widely in medical and scientific journals.

Education

Beijing University, China, Bsc, 1984-1987, Cell Biology and Genetics
Columbia University Medical School, New York, 1987-1989, Microbiology & Immunology
Stanford University School of Medicine, California, PhD, 1989-1995, Microbiology & Immunology
Stanford University School of Medicine, California, MD, 1996-2000, Medicine

Honors & Awards

  • 1997
    Beckman Scholar, Stanford University
  • 1998
    Dean's Scholar, Stanford University
  • 2005
    Young Investigator Award by American Society of Clinical Oncology (ASCO)
  • 2005
    Lisa Beth Fishman Memorial Fellow of Lymphoma Research Foundation (2005-2007)
  • 2006
    Travel Award by American Society of Hematology (ASH)
  • 2006
    Brigid G. Leventhal Scholar Awards by American Association for Cancer Research (AACR)

Selected Publications

  1. Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study. Haematologica. 2023 Aug 31.  View on PubMed
  2. Saglam A, Singh K, Kumar J, Gollapudi S, Mukherjee S, Singh A, Butzmann A, Kaplan L, Andreadis C, Ai WZ, Fakhri B, Rajkovic A, Wen KW, Onodera C, Van Ziffle J, Devine PW, Ohgami RS. Copy Number Loss at Chromosome 14q11.2 Correlates With the Proportion of T Cells in Biopsies and Helps Identify T-Cell Neoplasms. Arch Pathol Lab Med. 2023 08 01; 147(8):940-948.  View on PubMed
  3. Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, Okada C, Feldman TA, Ghione P, Alderuccio JP, Champion R, Kim SH, Mohrbacher A, Routhu KV, Barde P, Nair AM, Haverkos BM. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study. Haematologica. 2023 Jul 13.  View on PubMed
  4. Banerjee R, Wang V, Huang CY, Pandita D, Leonard MK, LaRue S, Ahmadi M, Kaplan L, Ai WZ, Fakhri B, Spinner M, Seshadri MR, Pampaloni MH, Andreadis CB. Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy. Eur J Nucl Med Mol Imaging. 2023 Jun 10.  View on PubMed
  5. Huang J, Xu Y, Li L, Ai W. The relationship between serum lipid and sudden sensorineural hearing loss. Acta Otolaryngol. 2023 Feb; 143(2):121-126.  View on PubMed
  6. Charli-Joseph Y, Pincus LB, Ai WZ. Prognostic Relevance of Dominant Blood T-Cell Clones in Early Mycosis Fungoides-Reply. JAMA Dermatol. 2023 01 01; 159(1):116-117.  View on PubMed
  7. Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Adv. 2022 08 23; 6(16):4736-4739.  View on PubMed
  8. Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022 08 04; 140(5):419-437.  View on PubMed
  9. Raychaudhuri S, Charli-Joseph Y, Huang CY, Mintz MA, Pincus LB, Ai WZ. Association of a Dominant T-Cell Clone in Peripheral Blood With Time to Systemic Treatment in Patients With Stage IB Mycosis Fungoides. JAMA Dermatol. 2022 08 01; 158(8):954-956.  View on PubMed
  10. Guan T, Lo M, Young R, Ai W, Boulbol F, Mouanoutoua H, Chu R, Andreadis C, Kaplan L, Abdulhaq H, Fakhri B. Evaluation of pulmonary toxicities in lymphoma patients receiving brentuximab vedotin. Leuk Lymphoma. 2022 Dec; 63(12):3008-3011.  View on PubMed
  11. Wu CH, Wang L, Yang CY, Wen KW, Hinds B, Gill R, McCormick F, Moasser M, Pincus L, Ai WZ. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Adv. 2022 04 12; 6(7):2290-2302.  View on PubMed
  12. Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Canc Netw. 2022 04; 20(4):322-334.  View on PubMed
  13. Kennedy VE, Huang CY, Kaplan LD, Andreadis C, Ai WZ, Olin RL. Geriatric assessment in adults age 50 years and older undergoing autologous hematopoietic cell transplantation for lymphoma. J Geriatr Oncol. 2022 06; 13(5):644-647.  View on PubMed
  14. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, Clemens MW, Dogan A, Foss F, Ghione P, Goodman AM, Guitart J, Halwani A, Haverkos BM, Hoppe RT, Jacobsen E, Jagadeesh D, Jones A, Kallam A, Kim YH, Kumar K, Mehta-Shah N, Olsen EA, Rajguru SA, Rozati S, Said J, Shaver A, Shea L, Shinohara MM, Sokol L, Torres-Cabala C, Wilcox R, Wu P, Zain J, Dwyer M, Sundar H. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 03; 20(3):285-308.  View on PubMed
  15. Hess B, Townsend W, Ai W, Stathis A, Solh M, Alderuccio JP, Ungar D, Liao S, Liao L, Khouri L, Zhang X, Boni J. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. AAPS J. 2021 12 10; 24(1):11.  View on PubMed
  16. Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai W, de la Cruz-Merino L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von Keudell GR, Lu H, Yakovich A, Chen M, Meulen Jh T, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leuk Lymphoma. 2022 04; 63(4):821-833.  View on PubMed
  17. Caimi PF, Ardeshna KM, Reid E, Ai W, Lunning M, Zain J, Solh M, Kahl BS, Hamadani M. The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. Clin Lymphoma Myeloma Leuk. 2022 05; 22(5):e335-e339.  View on PubMed
  18. Fakhri B, Ai W. Current and emerging treatment options in primary mediastinal B-cell lymphoma. Ther Adv Hematol. 2021; 12:20406207211048959.  View on PubMed
  19. Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):790-800.  View on PubMed
  20. Huang LW, Sun D, Link TM, Lang T, Ai W, Kaplan LD, Steinman MA, Andreadis C. High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas. Support Care Cancer. 2021 Sep; 29(9):5399-5408.  View on PubMed

Go to UCSF Profiles, powered by CTSI